Provectus Biopharmaceuticals, Inc. financial data

Symbol
PVCT on OTC
Location
Knoxville, TN
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 9.63 % -21.3%
Debt-to-equity -112 % +2.43%
Return On Equity 115 % +165%
Return On Assets -943 % -226%
Operating Margin -1.34K % -259%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 420M shares 0%
Common Stock, Shares, Outstanding 420M shares 0%
Entity Public Float 51.6M USD +13.4%
Common Stock, Value, Issued 420K USD 0%
Weighted Average Number of Shares Outstanding, Basic 420M shares +0.09%
Weighted Average Number of Shares Outstanding, Diluted 420M shares +0.09%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 460K USD -32.7%
Research and Development Expense 2.16M USD +16.2%
General and Administrative Expense 4.7M USD +182%
Operating Income (Loss) -6.51M USD -132%
Nonoperating Income (Expense) -230K USD -14.6%
Net Income (Loss) Attributable to Parent -6.63M USD -119%
Earnings Per Share, Basic 0 USD/shares 0%
Earnings Per Share, Diluted 0 USD/shares 0%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 72.5K USD -61.3%
Other Assets, Current 90.8K USD
Assets, Current 278K USD -63.4%
Property, Plant and Equipment, Net 3.47K USD -35%
Operating Lease, Right-of-Use Asset 138K USD +277%
Assets 420K USD -47.6%
Accounts Payable, Current 1.18M USD -14.7%
Employee-related Liabilities, Current 310K USD
Liabilities, Current 6.47M USD +3.97%
Operating Lease, Liability, Noncurrent 91.6K USD
Liabilities 6.59M USD +5.82%
Accumulated Other Comprehensive Income (Loss), Net of Tax -60.3K USD -0.21%
Retained Earnings (Accumulated Deficit) -262M USD -2.6%
Stockholders' Equity Attributable to Parent -6.15M USD -13.4%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -6.17M USD -13.7%
Liabilities and Equity 420K USD -47.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.09M USD -4.69%
Net Cash Provided by (Used in) Financing Activities 1.07M USD +37.4%
Common Stock, Shares Authorized 1B shares 0%
Common Stock, Shares, Issued 420M shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -20.3K USD +92.3%
Deferred Tax Assets, Valuation Allowance 47M USD -0.7%
Deferred Tax Assets, Gross 47.1M USD -0.76%
Operating Lease, Liability 139K USD +268%
Depreciation 467 USD -79.1%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -6.68M USD -119%
Lessee, Operating Lease, Liability, to be Paid 149K USD +287%
Operating Lease, Liability, Current 47.2K USD +25%
Lessee, Operating Lease, Liability, to be Paid, Year Two 25.7K USD +0%
Lessee, Operating Lease, Liability, to be Paid, Year One 12.8K USD -74.7%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure +40%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 10.2K USD +1186%
Deferred Tax Assets, Operating Loss Carryforwards 41.5M USD -1.03%
Preferred Stock, Shares Authorized 25M shares 0%
Operating Lease, Payments 12.6K USD +8.12%
Additional Paid in Capital 255M USD +2.37%
Share-based Payment Arrangement, Expense 1.28M USD -67.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%